{"chunk_type":"recap_summary","text":"# ğŸ”¥ Rapid Fire Recap\nê°•ì˜ì—ì„œ ë‹¤ë£¬ í•µì‹¬ ë‚´ìš©ì„ ë¹ ë¥´ê²Œ ì •ë¦¬í•©ë‹ˆë‹¤.\n1. **Dating Dilemma**\n    - **Scenario:** LMP vs Ultrasound ë‚ ì§œ ë¶ˆì¼ì¹˜ (íŠ¹íˆ 1ë¶„ê¸°).\n    - **Action:** â˜… **Trust the Ultrasound (CRL)**. Due dateëŠ” í•œ ë²ˆ ì •í•´ì§€ë©´ ë°”ë€Œì§€ ì•ŠìŒ.\n2. **Fetal Surveillance**\n    - **Scenario:** \"Baby isn't moving\" (Decreased fetal movement).\n    - **Action:** **NST** ë¨¼ì € ì‹œí–‰.\n    - **Result:** Non-reactive (No accelerations).\n    - **Next Step:** Vibroacoustic stimulation (Wake up baby) â†’ ê·¸ë˜ë„ ì•ˆ ë˜ë©´ **BPP**.\n    - **BPP Score:** 4ì  ì´í•˜ëŠ” **Immediate Delivery**.\n3. **Intrapartum Decelerations (VEAL CHOP)**\n    - **Variable Decels** â†’ **Cord Compression** â†’ **Reposition Mom**.\n    - **Late Decels** â†’ **Placental Insufficiency** â†’ **Intrauterine Resuscitation** (O2, IV, Stop Pitocin) â†’ Failì‹œ C-Section.\n    - **Sinusoidal** â†’ **Severe Fetal Anemia** â†’ Emergency.\n4. **Prenatal Genetic Screening**\n    - **Fact:** **NIPT** (Cell-free DNA)ëŠ” ì •í™•í•˜ì§€ë§Œ **Screening**ì´ë‹¤. í™•ì§„ì„ ìœ„í•´ì„œëŠ” **CVS**ë‚˜ **Amnio**ê°€ í•„ìš”í•˜ë‹¤.\n    - **Down Syndrome Pattern (Quad):** **HI**gh levels of **H**CG & **I**nhibin A.\n\"Welcome back. Today we're digging into a topic that's, well, it's absolutely critical in obstetrics. It really is. We're talking about congenital infections and screening. This is where, you know, maternal health and fetal outcomes collide and the margin for error is just so thin. Exactly. We're focusing on sections 4 through 4.6 of the material today. This is the bread and butter for the boards but it's also... I mean it's all about pattern recognition for real world practice. Pattern recognition, I like that. Yeah. You have to know who to screen, when to screen, and most importantly, how to stop that vertical transmission dead in its tracks.\"\n---\n# ğŸ“š USMLE Step 2 CK: Congenital Infections & Screening (Section 4 - 4.6)\nì•ˆë…•í•˜ì„¸ìš”! USMLE Step 2 ì¤€ë¹„í•˜ì‹œëŠë¼ ê³ ìƒ ë§ìœ¼ì‹­ë‹ˆë‹¤. ì—…ë¡œë“œí•´ì£¼ì‹  ì˜¤ë””ì˜¤ íŒŒì¼ì€ **Prenatal Screeningê³¼ Congenital Infections**ì— ëŒ€í•œ í•µì‹¬ ë‚´ìš©, íŠ¹íˆ **Vertical Transmission(ìˆ˜ì§ ê°ì—¼)**ì„ ë§‰ê¸° ìœ„í•œ Timingê³¼ Managementë¥¼ ë‹¤ë£¨ê³  ìˆìŠµë‹ˆë‹¤.\nìš”ì²­í•˜ì‹  ëŒ€ë¡œ **Top-down Classification (Structure)**ì„ ë¨¼ì € ë³´ì—¬ë“œë¦¬ê³ , ê° ì„¹ì…˜ë³„ í•µì‹¬ ë‚´ìš©ì„ ì •ë¦¬í•´ ë“œë¦´ê²Œìš”.\n## ğŸŒ³ Big Picture: Prenatal Screening Logic Tree","subject":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","page_title":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","episode":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","section_path":["LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12"],"source_doc_id":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","source_page":null,"source_anchor":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12-80","focus_area":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","tags":["usmle-step2","core","recap","diagnosis","treatment","tree"]}
{"chunk_type":"transcript_chunk","text":"ì˜¤ë””ì˜¤ì—ì„œ ê°•ì¡°í•œ \"Pattern Recognition\"ì„ ìœ„í•œ Mental Modelì…ë‹ˆë‹¤. ëˆ„êµ¬ë¥¼ ì–¸ì œ ìŠ¤í¬ë¦¬ë‹í•˜ê³  ì–´ë–»ê²Œ ë§‰ì„ ê²ƒì¸ê°€ì— ëŒ€í•œ êµ¬ì¡°ë„ì…ë‹ˆë‹¤.\nPlaintex\n`PRENATAL INFECTION SCREENING & MANAGEMENT\nâ”‚\nâ”œâ”€â”€ 1. Universal Screening (The \"Dragnet\" - First Visit)\nâ”‚   â”œâ”€â”€ Goal: ëª¨ë“  ì„ì‚°ë¶€ ëŒ€ìƒ ê¸°ë³¸ ê²€ì‚¬\nâ”‚   â”œâ”€â”€ Target Pathogens:\nâ”‚   â”‚   â”œâ”€â”€ HIV\nâ”‚   â”‚   â”œâ”€â”€ Syphilis (VDRL/RPR)\nâ”‚   â”‚   â”œâ”€â”€ Hepatitis B (HBsAg)\nâ”‚   â”‚   â””â”€â”€ Immunity Check: Rubella & Varicella\nâ”‚   â””â”€â”€ Action: ë©´ì—­ ì—†ìœ¼ë©´ ì¶œì‚° ì§í›„ ë°±ì‹  ì ‘ì¢… (ì„ì‹  ì¤‘ Live ë°±ì‹  ê¸ˆì§€!)\nâ”‚\nâ”œâ”€â”€ 2. High-Risk Screening (\"Widening the Aperture\")\nâ”‚   â”œâ”€â”€ Goal: Risk Factorê°€ ìˆëŠ” ì‚°ëª¨ ëŒ€ìƒ ì¶”ê°€ ê²€ì‚¬\nâ”‚   â”œâ”€â”€ Target Pathogens:\nâ”‚   â”‚   â”œâ”€â”€ Chlamydia & Gonorrhea (PCR)\nâ”‚   â”‚   â””â”€â”€ Hepatitis C, TB, etc.\nâ”‚   â””â”€â”€ Timing:\nâ”‚       â”œâ”€â”€ 1st Trimester (ì´ˆê¸°)\nâ”‚       â””â”€â”€ 3rd Trimester (Repeat screening at 28-32w) â˜… ì¤‘ìš”!\nâ”‚           (ì´ìœ : Window period ê³ ë ¤, ì„ì‹  ì¤‘ ì¬ê°ì—¼ ê°€ëŠ¥ì„±)\nâ”‚\nâ”œâ”€â”€ 3. Time-Sensitive Screening (Specific Windows)\nâ”‚   â””â”€â”€ GBS (Group B Strep): 36-38 Weeks (Transient colonization íŠ¹ì„± ë•Œë¬¸)\nâ”‚\nâ””â”€â”€ 4. Intrapartum Management (Delivery Room Decisions)\n    â”œâ”€â”€ Active HSV Lesions â†’ C-Section Mandatory\n    â”œâ”€â”€ HIV Viral Load > 1,000 â†’ C-Section Mandatory\n    â””â”€â”€ Syphilis/GBS Positive â†’ Intrapartum Penicillin`\n---\n## 1. Section 4: Congenital Infections Overview\nì„ì‹  ì¤‘ ê°ì—¼ ê´€ë¦¬ëŠ” **Prevention**ê³¼ **Screening Timing**ì´ í•µì‹¬ì…ë‹ˆë‹¤.\n### ğŸš© Screening Protocol\n- **Universal Screen (The Dragnet):** ëª¨ë“  ì‚°ëª¨ëŠ” ì²« ë°©ë¬¸ ì‹œ HIV, Syphilis, Hep B, Rubella/Varicella immunityë¥¼ ê²€ì‚¬í•©ë‹ˆë‹¤.\n- **High Risk Patients:** ë‚˜ì´ê°€ ì–´ë¦¬ê±°ë‚˜ (<25ì„¸), STIs ê³¼ê±°ë ¥ì´ ìˆëŠ” ê²½ìš° **Chlamydia & Gonorrhea** ìŠ¤í¬ë¦¬ë‹ì„ ì¶”ê°€í•©ë‹ˆë‹¤.\n    - â˜… **Key Point:** High risk í™˜ìëŠ” ì„ì‹  ì´ˆê¸° ìŒì„±ì´ë”ë¼ë„, **3rd Trimesterì— ì¬ê²€ì‚¬(Repeat screening)**ê°€ í•„ìˆ˜ì…ë‹ˆë‹¤. (Infectionì´ ì„ì‹  ì¤‘ê°„ì— ìƒê¸¸ ìˆ˜ ìˆìŒ)\n### ğŸ’‰ Vaccination Rules (Strict Guidelines)\nì˜¤ë””ì˜¤ì—ì„œ \"Hard Line\"ì´ë¼ê³  í‘œí˜„í•  ì •ë„ë¡œ ì—„ê²©í•œ ê·œì¹™ì…ë‹ˆë‹¤.\n| **Vaccine Type** | **Examples** | **Pregnancy Status** | **Reasoning** |\n| --- | --- | --- | --- |\n| **Live Attenuated** | **MMR, Varicella, Live Flu (Intranasal)** | âŒ **CONTRAINDICATED** | ì´ë¡ ì ìœ¼ë¡œ íƒœë°˜ì„ í†µê³¼í•´ íƒœì•„ ê°ì—¼ ê°€ëŠ¥ì„± ìˆìŒ (Risk of vertical transmission) |\n| **Inactivated / Toxoid** | **Tdap, Hep B, Inactivated Flu** | âœ… **SAFE / INDICATED** | Tdapì€ í•„ìˆ˜, ë‚˜ë¨¸ì§€ëŠ” Riskì— ë”°ë¼ ì ‘ì¢… ê°€ëŠ¥ |\n| **Special Situations** | Meningococcus, Pneumococcus, Hep A | âœ… Considered | High risk ìƒí™©ì¼ ê²½ìš° Benefit > Risk |\n---\n## 2. Section 4.1: Group B Strep (GBS)\nGBSëŠ” **Neonatal Sepsis**ì˜ ê°€ì¥ í”í•œ ì›ì¸ê· ì…ë‹ˆë‹¤.\n- **Why wait? (Timing is Key):** GBSëŠ” **Transient**í•©ë‹ˆë‹¤(ì™”ë‹¤ ê°”ë‹¤ í•¨). ì„ì‹  30ì£¼ì— ê²€ì‚¬í•˜ëŠ” ê±´ ì˜ë¯¸ê°€ ì—†ìŠµë‹ˆë‹¤. ë¶„ë§Œ ì‹œì ì— ê· ì´ ìˆëŠ”ì§€ ì•„ëŠ” ê²ƒì´ ì¤‘ìš”í•˜ë¯€ë¡œ **36~38ì£¼** ì‚¬ì´ì— ê²€ì‚¬í•©ë‹ˆë‹¤.\n- **Screening Method:** Rectovaginal culture.\n- **Treatment:** Culture Positiveë©´ ë¶„ë§Œ ì¤‘(Intrapartum) **Penicillin** (or Ampicillin) íˆ¬ì—¬.\n- **â“ Scenario: Preterm Labor (<37 weeks) with Unknown GBS Status**\n    - ê²€ì‚¬ ê²°ê³¼ê°€ ë‚˜ì˜¬ ë•Œê¹Œì§€ ê¸°ë‹¤ë¦´ ì‹œê°„ì´ ì—†ìŠµë‹ˆë‹¤. Preemie(ë¯¸ìˆ™ì•„)ëŠ” ê°ì—¼ì— ë§¤ìš° ì·¨ì•½í•©ë‹ˆë‹¤.\n    - **Action:** ë¬´ì¡°ê±´ **Treat immediately** (Start Penicillin). ë‚˜ì¤‘ì— ìŒì„± ë‚˜ì˜¤ë©´ ëŠë”ë¼ë„ ì¼ë‹¨ ì‹œì‘í•©ë‹ˆë‹¤.\n---\n## 3. Section 4.2: Syphilis (The \"Great Imitator\")\nìµœê·¼ ë‹¤ì‹œ ê¸‰ì¦í•˜ê³  ìˆëŠ” ì§ˆí™˜ì´ë©°, ì„ ì²œì„± ê°ì—¼ ì‹œ ê²°ê³¼ê°€ ì¹˜ëª…ì ì…ë‹ˆë‹¤.\n### ğŸ‘¶ Congenital Syphilis Signs\n- **Snuffles:** ì§€ì†ì ì¸ ì½§ë¬¼ (Persistent runny nose)\n- **Saber Shins:** ì •ê°•ì´ ë¼ˆê°€ ì•ìœ¼ë¡œ íœ˜ì–´ì§ (Tibia bows forward)\n- **Hutchinson Teeth:** í†±ë‹ˆ ëª¨ì–‘ì˜ ì•ë‹ˆ (Notched peg-shaped incisors)","subject":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","page_title":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","episode":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","section_path":["LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12"],"source_doc_id":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","source_page":null,"source_anchor":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12-90","focus_area":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","tags":["usmle-step2","core","treatment","mnemonic"]}
{"chunk_type":"transcript_chunk","text":"### ğŸ§ª Diagnosis Step-by-Step\n1. **Screening (Non-treponemal):** **VDRL** or **RPR**.\n    - **False Positive ì£¼ì˜:** ì„ì‹  ìì²´(Pregnancy), Lupus(SLE) ë“±ì—ì„œ ìœ„ì–‘ì„±ì´ ë‚˜ì˜¬ ìˆ˜ ìˆìŠµë‹ˆë‹¤. (ì—¼ì¦ ë°˜ì‘ë§Œ ë³´ëŠ” ê²ƒì„)\n2. **Confirmation (Treponemal):** **FTA-ABS**. (Specific antibody test)\n    - Screening ì–‘ì„±ì´ë©´ ë°˜ë“œì‹œ í™•ì§„ ê²€ì‚¬ë¥¼ í•´ì•¼ í•©ë‹ˆë‹¤.\n    - í™•ì§„ í›„ì—ëŠ” **Darkfield Microscopy**ë¡œ ê· (Spirochetes)ì„ ì§ì ‘ ë³¼ ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤.\n### ğŸ’Š Treatment & Dilemma\n- **Drug of Choice:** **Penicillin G**.\n- **â“ Scenario: Penicillin Allergyê°€ ìˆëŠ” ì„ì‚°ë¶€ë¼ë©´?**\n    - ë‹¤ë¥¸ ëŒ€ì•ˆ(Doxycycline ë“±)ì€ íƒœì•„ì—ê²Œ í•´ë¡­ê±°ë‚˜(Teeth discoloration) íš¨ê³¼ê°€ ë¶ˆí™•ì‹¤í•©ë‹ˆë‹¤.\n    - **Action:** **Desensitization (íƒˆê°ì‘)** í›„ Penicillinì„ íˆ¬ì—¬í•©ë‹ˆë‹¤. ì´ê²Œ ìœ ì¼í•œ ë°©ë²•ì…ë‹ˆë‹¤ (\"No alternative\").\n---\n## 4. Section 4.3: Rubella (German Measles)\n### ğŸš¨ Congenital Rubella Syndrome Triad (The 3 C's)\n1. **Cataracts** (White pupils) 2. **Cochlear defects** (Deafness)\n2. **Cardiac abnormalities** (ì£¼ë¡œ **PDA**)\n### ğŸ“… Timing & Management\n- **Infection < 16 Weeks:** íƒœì•„ì—ê²Œ ì¹˜ëª…ì (Catastrophic). ê¸°í˜• ë°œìƒ í™•ë¥  ë§¤ìš° ë†’ìŒ. â†’ **Counsel on Termination** ê³ ë ¤.\n- **Infection > 16 Weeks:** Riskê°€ ë‚®ì•„ì§. â†’ Reassurance.\n- **Prevention Strategy:**\n    - ì„ì‹  ì „ í˜¹ì€ ì²« ë°©ë¬¸ ì‹œ Rubella IgG(Immunity) í™•ì¸.\n    - **Non-immune ì‚°ëª¨:** ì„ì‹  ì¤‘ì—ëŠ” ë°±ì‹ (MMR) ì ‘ì¢… ë¶ˆê°€(Live vaccine). **ì¶œì‚° ì§í›„(Postpartum)** í‡´ì›í•˜ê¸° ì „ì— ë°±ì‹ ì„ ë§ì¶¥ë‹ˆë‹¤.\n---\n## 5. Section 4.4: HSV (Herpes Simplex Virus)\nì‹ ìƒì•„ì—ê²ŒëŠ” Brain, Skin, Eyesì— ì¹˜ëª…ì ì¸ ê°ì—¼ì„ ì¼ìœ¼í‚¬ ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n- **The Rule:** ë¶„ë§Œ ì‹œì ì— **Active Genital Lesions**ì´ ìˆê±°ë‚˜ **Prodromal symptoms**(íƒ€ëŠ” ë“¯í•œ ëŠë‚Œ ë“±)ì´ ìˆìœ¼ë©´?\n- **Action:** **C-Section Mandatory**. (Vaginal delivery ê¸ˆì§€).\n- **Prophylaxis:** ì¬ë°œ ë°©ì§€ë¥¼ ìœ„í•´ ì„ì‹  36ì£¼ë¶€í„° Acyclovir ì˜ˆë°© ìš”ë²•ì„ í•˜ê¸°ë„ í•©ë‹ˆë‹¤ (ì˜¤ë””ì˜¤ì—ëŠ” êµ¬ì²´ì  ì•½ë¬¼ ì–¸ê¸‰ë³´ë‹¤ C-sec ê°•ì¡°ë¨).\n---\n## 6. Section 4.6: HIV\nê°€ì¥ ê·œì •ì´ ì—„ê²©í•˜ì§€ë§Œ, ê´€ë¦¬ë§Œ ì˜í•˜ë©´ ìˆ˜ì§ ê°ì—¼ì„ ê±°ì˜ 0%ë¡œ ë§Œë“¤ ìˆ˜ ìˆëŠ” ë¶„ì•¼ì…ë‹ˆë‹¤.\n### ğŸ”¢ The Magic Number: 1,000 copies/mL\nViral Load(ë°”ì´ëŸ¬ìŠ¤ ìˆ˜ì¹˜)ê°€ **1,000**ì„ ê¸°ì¤€ìœ¼ë¡œ ëª¨ë“  ê²ƒì´ ê²°ì •ë©ë‹ˆë‹¤.\n| **Viral Load** | **Delivery Method** | **Management** |\n| --- | --- | --- |\n| **> 1,000 copies/mL** | **C-Section Mandatory** | Vaginal delivery ì‹œ ê°ì—¼ ìœ„í—˜ ë„ˆë¬´ ë†’ìŒ. Zidovudine(AZT) IV during labor. |\n| **< 1,000 copies/mL** (on HAART) | **Vaginal Delivery OK** | ì•½ ì˜ ë¨¹ê³  ë°”ì´ëŸ¬ìŠ¤ ì–µì œë˜ë©´ ìì—°ë¶„ë§Œ ì•ˆì „í•¨. |","subject":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","page_title":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","episode":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","section_path":["LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12"],"source_doc_id":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","source_page":null,"source_anchor":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12-110","focus_area":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","tags":["usmle-step2","core","diagnosis","treatment"]}
{"chunk_type":"transcript_chunk","text":"### ğŸš« Intrapartum \"Don'ts\" (ê¸ˆê¸°ì‚¬í•­)\nì‚°ëª¨ì˜ í˜ˆì•¡ê³¼ íƒœì•„ì˜ í˜ˆì•¡ì´ ì„ì´ëŠ” ìƒí™©ì„ í”¼í•´ì•¼ í•©ë‹ˆë‹¤.\n- NO Artificial Rupture of Membranes (ì–‘ë§‰ ì¸ê³µ íŒŒì—´ ê¸ˆì§€ - ê°€ëŠ¥í•œ í•œ ëŠ¦ê²Œ)\n- NO Fetal Scalp Electrodes (íƒœì•„ ë¨¸ë¦¬ì— ì „ê·¹ ê½‚ê¸° ê¸ˆì§€)\n- NO Vacuum or Forceps (ê¸°êµ¬ ë¶„ë§Œ ê¸ˆì§€)\n### ğŸ‘¶ Infant Diagnosis\n- **Mom's IgG crosses the placenta:** ì—„ë§ˆì˜ í•­ì²´ê°€ ì•„ê¸°ì—ê²Œ ë„˜ì–´ê°€ë¯€ë¡œ, ì•„ê¸°ì—ê²Œ í•­ì²´ ê²€ì‚¬(ELISA/Western Blot)ë¥¼ í•˜ë©´ **ë¬´ì¡°ê±´ ì–‘ì„±** ë‚˜ì˜µë‹ˆë‹¤ (ìµœëŒ€ 18ê°œì›”ê¹Œì§€).\n- **Action:** ì•„ê¸°ì˜ ì§„ë‹¨ì€ **HIV DNA PCR** (ë°”ì´ëŸ¬ìŠ¤ ìì²´ ê²€ì¶œ)ë¡œ í•´ì•¼ í•©ë‹ˆë‹¤.\n---\n## ğŸ”¥ Rapid Fire Recap (ìš”ì•½)\nì˜¤ë””ì˜¤ì˜ ë§ˆì§€ë§‰ í€´ì¦ˆ ì„¹ì…˜ì„ ì •ë¦¬í–ˆìŠµë‹ˆë‹¤.\n- **Scenario 1:** ì‹ ìƒì•„ê°€ ë°±ë‚´ì¥(Cataracts), ë‚œì²­(Deafness), ì‹¬ì¥ ê¸°í˜•(PDA)ì„ ë³´ì„.\n    - ğŸ‘‰ **Diagnosis:** **Congenital Rubella Syndrome**.\n- **Scenario 2:** ì‹ ìƒì•„ê°€ ì½§ë¬¼(Snuffles), ì •ê°•ì´ íœ¨(Saber shins), Hutchinson teethë¥¼ ë³´ì„.\n    - ğŸ‘‰ **Diagnosis:** **Congenital Syphilis**.\n- **Scenario 3:** ì„ì‚°ë¶€ Syphilis ì–‘ì„±ì¸ë° Penicillin Allergyê°€ ìˆìŒ.\n    - ğŸ‘‰ **Key Action:** **Desensitization** í›„ Penicillin íˆ¬ì—¬ (Don't switch drugs).\n- **Scenario 4:** HIV ì‚°ëª¨, Viral load < 1,000 copies. ë¶„ë§Œ ë°©ë²•ì€?\n    - ğŸ‘‰ **Key Action:** **Vaginal Delivery** ê°€ëŠ¥.\n- **Scenario 5:** Preterm labor (33ì£¼), GBS ìƒíƒœ ëª¨ë¦„.\n    - ğŸ‘‰ **Key Action:** ì¼ë‹¨ **Penicillin** ì‹œì‘ (Treat as positive).\n- **Scenario 6:** ì„ì‹  ì¤‘ MMR ë°±ì‹  ì ‘ì¢… ê°€ëŠ¥?\n    - ğŸ‘‰ **Fact:** ì ˆëŒ€ ë¶ˆê°€ (**Live Vaccine** Contraindicated). ì¶œì‚° í›„ ì ‘ì¢….\n---\n**Would you like me to create a specific Anki card style Q&A list for these infection protocols to help with your spaced repetition?**\n### Summary & Vibe\n**One Line Vibe:** ë¼ìš´ë”© ì „ 18ë¶„, ì—ìŠ¤í”„ë ˆì†Œ í•œ ì”ê³¼ í•¨ê»˜ OBGYN High-yield \"Scary Stuff\" ì™„ë²½ ì •ë¦¬! â˜•ğŸ¥\n---\n---\n### **Medical Concept Tree (Top-down Classification)**\nPlaintext\n`Obstetrics (High-Yield Pathology)\nâ”œâ”€â”€ Section 5: IUGR (Intrauterine Growth Restriction)\nâ”‚   â”œâ”€â”€ Etiology: Maternal HTN â†’ Placental Insufficiency\nâ”‚   â”œâ”€â”€ Pathophysiology:\nâ”‚   â”‚   â”œâ”€â”€ Brain Sparing Effect (Shunt blood to vital organs)\nâ”‚   â”‚   â””â”€â”€ Renal hypoperfusion â†’ Oligohydramnios\nâ”‚   â””â”€â”€ Management Decision: Umbilical Artery Doppler (Resistance Gauge)\nâ”‚       â”œâ”€â”€ High Resistance: Monitor\nâ”‚       â””â”€â”€ Reverse End-Diastolic Flow: Immediate Delivery (C-Sec)\nâ”‚\nâ”œâ”€â”€ Section 6: Twins (Multiple Gestation)\nâ”‚   â”œâ”€â”€ Risks: Hyperemesis (â†‘hCG), Pre-eclampsia (â†‘Placental mass), Vasa Previa\nâ”‚   â”œâ”€â”€ Delivery Management (Based on Twin A)\nâ”‚   â”‚   â”œâ”€â”€ Twin A Vertex: Vaginal Delivery possible (even if B is breech)\nâ”‚   â”‚   â””â”€â”€ Twin A Breech: C-Section\nâ”‚   â””â”€â”€ Contraindications: External Cephalic Version (ECV) - Absolute NO\nâ”‚\nâ”œâ”€â”€ Section 7: IUFD (Intrauterine Fetal Demise)\nâ”‚   â”œâ”€â”€ Diagnosis: Real-time Ultrasound (Absence of cardiac activity)\nâ”‚   â”œâ”€â”€ Management: Vaginal Delivery (Induction) > C-Section\nâ”‚   â”‚   â””â”€â”€ Why? Protect future reproductive health (avoid uterine scar)\nâ”‚   â””â”€â”€ Complications: DIC (Thromboplastin release from retained fetus)\nâ”‚\nâ””â”€â”€ Section 8: Hydrops Fetalis\n    â”œâ”€â”€ Definition: Fluid in 2+ compartments (Skin edema, ascites, effusion)\n    â”œâ”€â”€ Mechanism: High Output Heart Failure (Severe Anemia)\n    â””â”€â”€ Causes:\n        â”œâ”€â”€ Immune: Rh Incompatibility\n        â””â”€â”€ Non-Immune: Parvovirus B19 (BM suppression), Alpha-Thalassemia (Hb Barts)`","subject":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","page_title":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","episode":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","section_path":["LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12"],"source_doc_id":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","source_page":null,"source_anchor":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12-130","focus_area":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","tree"]}
{"chunk_type":"transcript_chunk","text":"---\n# [Sections 5-8] Managing IUGR, Twins, Demise, and Hydrops\n## 1. Introduction\n- **Context:** ë¼ìš´ë”© ì‹œì‘ ì „ 18ë¶„ ë™ì•ˆ **\"The Scary Stuff\"** (ë°¤ ë‹¹ì§ ë•Œ ì½œ ë°›ëŠ” ì‘ê¸‰ ìƒí™©ë“¤)ë¥¼ ì •ë¦¬í•˜ëŠ” ì‹œê°„.\n- **Topics:** Normal laborëŠ” ìŠ¤í‚µí•˜ê³ , IUGR, Twins, Fetal Demise, Hydrops ê°™ì€ High-yield pathologyì— ì§‘ì¤‘.\n---\n## 2. Section 5: IUGR (Intrauterine Growth Restriction)\n**Clinical Scenario:**\n- 32ì£¼ ì‚°ëª¨, **Chronic Hypertension** history.\n- **Fundal height**ê°€ 4cm ì •ë„ ì‘ê²Œ ì¸¡ì •ë¨ (Lagging behind).\n**Workup Flow:**\n1. **Initial:** Bio-physical Profile (BPP) & Ultrasound (Estimated Fetal Weight < 10th percentile).\n2. **Most Critical Step:** â˜… **Umbilical Artery Doppler**\n    - DopplerëŠ” Placental bedì˜ **Resistance**ë¥¼ ì¸¡ì •í•˜ëŠ” Pressure gauge ì—­í• ì„ í•¨.\n    - Healthy Placenta = Low resistance sponge (íƒœì•„ ì‹¬ì¥ ì´ì™„ê¸°ì—ë„ íƒœì•„ì—ì„œ íƒœë°˜ìª½ìœ¼ë¡œ í”¼ê°€ ì˜ íë¦„).\n    - Calcified/Old Placenta (HTN) = High resistance brick. (íƒœë°˜ ì••ë ¥ì´ ë†’ì•„ì„œ íƒœì•„ ì‹¬ì¥ ì´ì™„ê¸°ë§Œí¼ ë†’ì•„ì§€ë©´ íƒœì•„ìª½ì—ì„œ íƒœë°˜ìª½ìœ¼ë¡œ í”¼ê°€ ì•ˆê°)\n**Doppler Findings & Management:**\n- **Reduced Diastolic Flow:** Resistanceê°€ ì˜¬ë¼ê°€ì„œ ì´ì™„ê¸°ì— í”¼ê°€ ì˜ ì•ˆ ê°. (ì••ë ¥ì´ ë†’ì•„ì„œ íƒœì•„ì—ì„œ íƒœë°˜ìœ¼ë¡œ ì˜ ì•ˆê°„ë‹¤)\n- **Absent End-Diastolic Flow:** ì´ì™„ê¸°ì— í”¼ê°€ ë©ˆì¶¤. íƒœë°˜ ì••ë ¥ì´ íƒœì•„ ì‹¬ì¥ ì´ì™„ê¸°ì••ë ¥ë§Œí¼ ë†’ì•„ì ¸ì„œ ì•ˆê°. í‰í˜•ì„ ì´ë£¬ìƒíƒœ\n- **Reverse End-Diastolic Flow (The Ominous Sign):**\n    - íƒœì•„ ìª½ ì••ë ¥ë³´ë‹¤ íƒœë°˜ ì €í•­ì´ ë” ì»¤ì„œ í”¼ê°€ íƒœì•„ ìª½ìœ¼ë¡œ ì—­ë¥˜í•¨.\n    - **Action:** â˜… **Immediate Delivery (usually C-section)**. íƒœì•„ê°€ ìˆ¨ì„ ëª» ì‰¬ëŠ” ìƒíƒœ(Suffocating).\n**Pathophysiology (Why Oligohydramnios?):**\n- **Brain Sparing Effect:** Fetusê°€ Hypoxiaë¥¼ ê°ì§€í•˜ë©´ Vital organs (Brain, Heart)ë¡œ í”¼ë¥¼ ëª°ì•„ì¤Œ (Sympathetic response).\n    - Kidneyë¡œ ê°€ëŠ” í˜ˆë¥˜ ê°ì†Œ  â†’ Urine production ê°ì†Œ  â†’ Amniotic fluid (mostly fetal urine) ê°ì†Œ  â†’ **Oligohydramnios**.\n---\n## 3. Section 6: Twins\n**Key Physiological Changes:**\n- **Hyperemesis Gravidarum:** Placental massê°€ ì»¤ì„œ **hCG**ê°€ í­ë°œì ìœ¼ë¡œ ì¦ê°€  â†’ ì‹¬í•œ êµ¬í† .\n- **Pre-eclampsia:** Placental mass ì¦ê°€ë¡œ ì¸í•œ Vascular strain  â†’ ì‚°ëª¨ì˜ ê³ í˜ˆì•• ìœ„í—˜ ê¸‰ì¦.","subject":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","page_title":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","episode":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","section_path":["LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12"],"source_doc_id":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","source_page":null,"source_anchor":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12-150","focus_area":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","tree"]}
{"chunk_type":"transcript_chunk","text":"**Delivery Management Dilemma (Board Trap! ğŸš©):**\nTwin A(ì•„ë˜ìª½ ì•„ê¸°)ì˜ ìœ„ì¹˜ê°€ ê²°ì •ì ì„.\n![image.png](LM_obs1/image.png)\n- **External Cephalic Version (ECV):** Twinsì—ì„œëŠ” **Absolute Contraindication**. (ìœ„í—˜í•¨: Placental abruption, cord entanglement ë“±).\n- **Vasa Previa:** IVFë‚˜ Twinsì—ì„œ ë¹ˆë„ê°€ ë†’ìŒ. Vesselì´ Internal osë¥¼ ê°€ë¡œì§€ë¦„  â†’ ì–‘ë§‰ íŒŒì—´ ì‹œ íƒœì•„ í˜ˆê´€ì´ ì°¢ì–´ì§  â†’ **Fetal Exsanguination** (ì¦‰ì‹œ C/S í•„ìš”).\n---\n## 4. Section 7: Demise (IUFD - Intrauterine Fetal Demise)\n**Diagnosis:**\n- í™˜ìê°€ \"ì´í‹€ ë™ì•ˆ íƒœë™ì´ ì—†ì–´ìš”\"ë¼ê³  í•¨.\n- Dopplerë¡œ ì‹¬ë°•ë™ ì•ˆ ë“¤ë¦¼  â†’ **Real-time Ultrasound**ë¡œ í™•ì§„ (Cardiac activity ì—†ëŠ” ê²ƒ í™•ì¸).\n**Management (The Counter-intuitive Part):**\n- **Scenario:** 34ì£¼ IUFD, ì‚°ëª¨ëŠ” ìŠ¬í¼í•˜ë©° ë‹¹ì¥ ìˆ˜ìˆ (C-section)ì„ ì›í•¨.\n- **Doctor's Decision:** â˜… **Vaginal Delivery (Induction of Labor)**\n    - **Why?** C-sectionì€ ìê¶ì— ì˜êµ¬ì ì¸ í‰í„°(Scar)ë¥¼ ë‚¨ê²¨ ë‹¤ìŒ ì„ì‹  ì‹œ **Uterine Rupture** ìœ„í—˜ì„ ë†’ì„. ì£½ì€ íƒœì•„ë¥¼ ìœ„í•´ ì‚°ëª¨ì˜ ë¯¸ë˜ ìƒì‹ ëŠ¥ë ¥ì„ í¬ìƒí•  ìˆ˜ ì—†ìŒ (Maternal morbidity ìµœì†Œí™”).\n    - **Exceptions for C-section:**\n        1. Prior Classical C-section (Vertical scar).\n        2. Placenta Previa (ì§ˆì‹ ë¶„ë§Œ ë¶ˆê°€ëŠ¥).\n        3. Emergency maternal indication.\n**Risks of Waiting (Retention of Dead Fetus): ì•„ë¬´ê²ƒë„ ì•ˆí•˜ê³  ì§‘ê°€ì„œ ì£½ì€ íƒœì•„ê°€ ì•Œì•„ì„œ ë‚˜ì˜¬ë•Œê¹Œì§€ ê¸°ë‹¤ë¦¬ë©´ ì•ˆë˜ëŠ” ì´ìœ :**\n- **Coagulopathy (DIC):** íƒœì•„ ì¡°ì§ì´ ë¶„í•´ë˜ë©´ì„œ **Thromboplastin**ì´ ëª¨ì²´ í˜ˆì•¡ìœ¼ë¡œ ìœ ì…  â†’ Clotting factors ì†Œëª¨  â†’ Uncontrolled Bleeding.\n- ë”°ë¼ì„œ ë„ˆë¬´ ì˜¤ë˜ ê¸°ë‹¤ë¦¬ì§€ ì•Šê³  **Induction** ê¶Œì¥.\n---\n## 5. Section 8: Hydrops Fetalis\n**Definition:**\n- Abnormal fluid accumulation in **2 or more compartments** (Skin edema, Ascites, Pleural effusion, Pericardial effusion).\n- Placentaë„ ë‘êº¼ì›Œì§ (Placentomegaly).\n**Mechanism:**\n- **Severe Anemia**  â†’ Heart tries to compensate (High output)  â†’ **High Output Heart Failure**  â†’ Venous pressure ì¦ê°€  â†’ Fluid leakage (Hydrops).","subject":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","page_title":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","episode":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","section_path":["LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12"],"source_doc_id":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","source_page":null,"source_anchor":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12-170","focus_area":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"**Causes:**\n1. **Immune:** **Rh Incompatibility** (Mom Rh-, Baby Rh+). ì—„ë§ˆ í•­ì²´ê°€ ì•„ê¸° RBC ê³µê²© (Hemolysis). (RhoGAMìœ¼ë¡œ ì˜ˆë°© ê°€ëŠ¥í•´ì ¸ì„œ ìš”ì¦˜ì€ ë“œë¬¾).\n2. **Non-Immune (Most common now):**\n    - â˜… **Parvovirus B19:** ê³¨ìˆ˜(Bone marrow)ë¥¼ ê°ì—¼ì‹œì¼œ RBC ìƒì‚° ì¤‘ë‹¨  â†’ Severe Anemia.\n    - **Alpha-Thalassemia Major (Hb Barts):** 4ê°œ ìœ ì „ì ëª¨ë‘ ê²°ì† (Deletion). ì‚°ì†Œ ì¹œí™”ë ¥ì´ ë„ˆë¬´ ë†’ì•„ ì¡°ì§ì— ì‚°ì†Œë¥¼ ì•ˆ ì¤Œ  â†’ Fetal suffocation & Heart failure.\n    - Genetic: Turner syndrome(lymphatic destruction), Down syndrome(Heart defects)\n---\n### ğŸ”¥ Rapid Fire Recap\n1. **IUGR + Reverse End-Diastolic Flow**  â†’ **Diagnosis:** Fetal Hypoxia/Suffocation  â†’ **Action:** Immediate Delivery (C-Sec).\n2. **Twins + Twin A is Breech**  â†’ **Diagnosis:** Malpresentation risk  â†’ **Action:** C-Section (No ECV!).\n3. **IUFD (Fetal Death) Diagnosis**  â†’ **Key Tool:** Real-time Ultrasound (NOT just Doppler).\n4. **IUFD Management**  â†’ **Goal:** Protect future uterus  â†’ **Action:** Vaginal Delivery (Induction).\n5. **Hydrops Fetalis**  â†’ **Pathophysiology:** Severe Anemia  â†’ High Output Heart Failure.\n    1. Rh, Parvo B19, ì—¼ìƒ‰ì²´ë¬¸ì œ (Down, turner), Hb Barts (alpha ì§€ì¤‘í•´ì„±ë¹ˆí˜ˆ)\n6. **Parvovirus B19 in Pregnancy**  â†’ **Mechanism:** Attacks Erythroid precursors  â†’ Aplastic Anemia  â†’ Hydrops.\n\"Welcome back to the wards. If you were listening to this, you've likely traded your sleep schedule for a pager and a white coat that's seen better days. Oh for sure. Grab your stethoscope and maybe a double shot of espresso black, no sugar. Because today, we are stepping onto the labor and delivery floor. And we aren't heading to the low risk birthing suites with the dim lighting of the jacuzzis, we are walking straight into the high acuity zone. Yeah. We are doing a deep dive into the absolute bread and butter but also the potential killers of obstetrics.\"\n---\n# Section 9: Hypertensive Disorders of Pregnancy (USMLE Step 2 CK)\nì•ˆë…•í•˜ì„¸ìš”! USMLE Step 2 CK OB/GYN íŒŒíŠ¸ ì¤‘ ê°€ì¥ ì¤‘ìš”í•˜ê³  ìœ„í—˜í•œ **Hypertensive Disorders**ë¥¼ ì •ë¦¬í•´ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì‹œí—˜ì— ë¬´ì¡°ê±´ ë‚˜ì˜¤ëŠ” High Yield í† í”½ì…ë‹ˆë‹¤. ğŸš‘ğŸ¤°\n## 1. Big Picture & Pathophysiology ğŸ§ \nì´ ì£¼ì œì˜ í•µì‹¬ì€ **\"20-week line in the sand\"**ì…ë‹ˆë‹¤. ì„ì‹  20ì£¼ë¥¼ ê¸°ì¤€ìœ¼ë¡œ ë³‘íƒœìƒë¦¬ì™€ ì§„ë‹¨ì´ ì™„ì „íˆ ê°ˆë¦½ë‹ˆë‹¤.\n### **Mental Model: The Placenta is the Culprit**\nì™œ 20ì£¼ê°€ ì¤‘ìš”í• ê¹Œìš”? ë°”ë¡œ **Placenta Remodeling** ë•Œë¬¸ì…ë‹ˆë‹¤.\n- **Normal Physiology:** Trophoblast cellsê°€ ìê¶ì˜ Spiral arteriesë¥¼ ì¹¨íˆ¬í•˜ì—¬, ì¢ê³  ì €í•­ì´ ë†’ì€ í˜ˆê´€ì„ **Wide, Low-resistance pools**ë¡œ ë¦¬ëª¨ë¸ë§í•©ë‹ˆë‹¤. ì´ ê³¼ì •ì´ ë³´í†µ 20ì£¼ì— ì™„ë£Œë©ë‹ˆë‹¤.\n- **Pathology:** ì´ ë¦¬ëª¨ë¸ë§ì´ ì‹¤íŒ¨í•˜ë©´(shallow invasion), í˜ˆê´€ì´ ì—¬ì „íˆ ë»£ë»£í•˜ê³  ì €í•­ì´ ë†’ìŠµë‹ˆë‹¤(High resistance). ê²°ê³¼ì ìœ¼ë¡œ íƒœë°˜ì— í˜ˆë¥˜ ê³µê¸‰ì´ ë¶€ì¡±í•´ì§€ê³ (Ischemia), \"í™”ê°€ ë‚œ\" íƒœë°˜ì´ ì—„ë§ˆ í˜ˆì•¡ìœ¼ë¡œ **Anti-angiogenic factors**ë¥¼ ë¿œì–´ë‚´ì–´ ì „ì‹ ì ì¸ í˜ˆê´€ ì†ìƒ(Endothelial damage)ì„ ì¼ìœ¼í‚µë‹ˆë‹¤.\n`OBSTETRICS_PATHOLOGY\n â”œâ”€â”€ < 20 Weeks Gestation\n â”‚    â””â”€â”€ Chronic Hypertension (Pre-existing vascular pathology)\n â”‚\n â””â”€â”€ â‰¥ 20 Weeks Gestation (Placental Issue)\n      â”œâ”€â”€ No Proteinuria/End-organ damage\n      â”‚    â””â”€â”€ Gestational Hypertension\n      â”‚\n      â””â”€â”€ Proteinuria OR End-organ damage present\n           â”œâ”€â”€ Preeclampsia (Mild)\n           â”œâ”€â”€ Preeclampsia with Severe Features (The Danger Zone ğŸš¨)\n           â”‚    â”œâ”€â”€ BP â‰¥ 160/110\n           â”‚    â”œâ”€â”€ End-organ damage (Liver, Kidney, Lung, Brain)\n           â”‚    â””â”€â”€ HELLP Syndrome\n           â”‚\n           â””â”€â”€ Eclampsia (Seizures âš¡ï¸)`\n---\n## 2. Diagnosis & The Spectrum of Disease ğŸ“Š\ní˜ˆì•• ê¸°ì¤€: **Systolic â‰¥ 140 OR Diastolic â‰¥ 90** (4ì‹œê°„ ê°„ê²© 2íšŒ ì¸¡ì •)\nì ˆëŒ€ í•œ ë²ˆì˜ ì¸¡ì •ìœ¼ë¡œ ì§„ë‹¨í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤ (White coat syndrome ë°°ì œ).","subject":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","page_title":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","episode":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","section_path":["LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12"],"source_doc_id":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","source_page":null,"source_anchor":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12-190","focus_area":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","mnemonic","tree"]}
{"chunk_type":"transcript_chunk","text":"### **Classification Table**\n| **Disorder** | **Timing** | **Key Features** | **Proteinuria?** |\n| --- | --- | --- | --- |\n| **Chronic Hypertension** | < 20 Weeks | ì„ì‹  ì „ë¶€í„° ìˆì—ˆê±°ë‚˜ 20ì£¼ ì´ì „ì— ë°œê²¬ë¨. | (-/+) Baselineì¼ ìˆ˜ ìˆìŒ |\n| **Gestational Hypertension** | â‰¥ 20 Weeks | 20ì£¼ ì´í›„ ë°œìƒ, ì¶œì‚° í›„ 12ì£¼ ë‚´ ì •ìƒí™”. | **Negative** |\n| **Preeclampsia** | â‰¥ 20 Weeks | New onset HTN + ë‹¨ë°±ë‡¨ í˜¹ì€ End-organ damage. | **Positive** or End-organ signs |\n| **Superimposed Preeclampsia** | Chronic HTN í™˜ì | ê°‘ì‘ìŠ¤ëŸ¬ìš´ BP ì•…í™”\ní˜¹ì€ ìƒˆë¡œìš´ ë‹¨ë°±ë‡¨/ì¥ê¸° ì†ìƒ ë°œìƒ. | **New/Worsening** |\n| **Eclampsia** | Any | Preeclampsia\n+ **Seizures** (Grand mal). | Yes |\n### Preeclampsia\n- 20ì£¼ì´í›„!\n### **â˜… Preeclampsia with Severe Features Criteria (Must Memorize)**\në‹¨ìˆœ Preeclampsiaì™€ ë‹¬ë¦¬ ì¦‰ê°ì ì¸ ì²˜ì¹˜ê°€ í•„ìš”í•©ë‹ˆë‹¤. ë‹¤ìŒ ì¤‘ í•˜ë‚˜ë¼ë„ ìˆìœ¼ë©´ í•´ë‹¹ë©ë‹ˆë‹¤. â†’ induction or c-sec\n  BP â†‘\n  thrombocytopenia (ì—¬ëŸ¬êµ°ë°ì„œ microthrombi â†’ í˜ˆì „ë§Œë“¤ì–´ì§)\n- ìœ íš¨í˜ˆë¥˜ëŸ‰ ê°ì†Œ / ì´ìƒí•œë° í”¼ê°€ ë§ë‹¤.\n  AKI\n- permeability â†‘\n- albuin loss â†’ ìŠ¤í€ì§€ê°€ ì—†ìŒ â†’ ë‹¤ë¥¸ë°ê°€ ë¶€ìŒ\n  ë‡Œë¶€ì¢… (ì‹œì•¼ì´ìƒ, ë°œì‘)\n  ê°„ë¶€ì „\n- **Blood Pressure:** SBP â‰¥ 160 or DBP â‰¥ 110 (Stroke risk!)\n- **Platelets:** < 100,000 (Thrombocytopenia) (microvascular consumption, thrombus everywhere)\n- **Liver:** LFTs 2x Upper Limit, Severe RUQ/Epigastric pain (Glisson's capsule stretching)\n- **Kidney:** Cr > 1.1 or doubling of baseline (Renal insufficiency)\n- **Lungs:** Pulmonary Edema (Flash edema) (Albumin drops. í”¼ì•ˆì— ìŠ¤í€ì§€ ì—†ìŒ. â†’ í, ì‹ ì¥ë¶€ì „)\n- **Brain:** New onset headache unresponsive to meds, visual disturbances. (ë‡Œë¶€ì¢…)\n### Eclampsia\n- seizure\n- baby decel:\n- management:\n    1. magnesium\n    2. stable the mother (airway, ì™¼ìª½ìœ¼ë¡œ ëŒë ¤ì„œ í˜ˆë¥˜ëŸ‰ ê°œì„ )\n    3. â˜… DELIVERY\n\n        note: active ë°œì‘ ì¤‘ì—ëŠ” c-secí•˜ì§€ ì•ŠìŒ. stabilize â†’ deliver\n---\n## 3. Management & Pharmacology ğŸ’Š\në‘ ëª…ì˜ í™˜ì(Mom & Baby)ë¥¼ ë™ì‹œì— ê³ ë ¤í•´ì•¼ í•©ë‹ˆë‹¤.\n### **Anti-hypertensives (Maternal Safety)**\níƒœë°˜ í˜ˆë¥˜ë¥¼ ìœ ì§€í•˜ë©´ì„œ ì—„ë§ˆì˜ ë‡Œì¶œí˜ˆì„ ë§‰ì•„ì•¼ í•©ë‹ˆë‹¤.\n- **Methyldopa (The Grandma):** Alpha-2 agonist. ì•„ì£¼ ì•ˆì „í•˜ì§€ë§Œ ì•½íš¨ê°€ ì•½í•¨.\n- **Labetalol (The Workhorse):** Alpha/Beta blocker. íƒœë°˜ í˜ˆë¥˜ ìœ ì§€ì— ì¢‹ìŒ. **ì²œì‹(Asthma)ì´ë‚˜ ì„œë§¥(Bradycardia)** í™˜ìì—ì„œëŠ” í”¼í•  ê²ƒ. IV ê¸‰ì„±ê¸°ì‚¬ìš©.\n- **Hydralazine:** Direct vasodilator. ê¸‰ì„±ê¸° ì¡°ì ˆì— ì‚¬ìš© (IV).\n- **Nifedipine:** Calcium Channel Blocker (Oral). ì‘ê¸‰ ì‹œë‚˜ ìœ ì§€ ìš”ë²• ì‚¬ìš©.","subject":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","page_title":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","episode":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","section_path":["LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12"],"source_doc_id":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","source_page":null,"source_anchor":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12-210","focus_area":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","tags":["usmle-step2","core","treatment"]}
{"chunk_type":"transcript_chunk","text":"- **ACEi, ARBsëŠ” ì ˆëŒ€ ê¸ˆê¸°** (Renal dysgenesis, Oligohydramnios ìœ ë°œ).\n- ì´ë‡¨ì œ ê¸ˆì§€: puffyí•´ë³´ì—¬ë„ dry inside (â†“ intravascular volume)\n### **Seizure Prophylaxis: Magnesium Sulfate (MgSo4)** âš¡ï¸\n- **ëª©ì :** í˜ˆì•• ì¡°ì ˆìš©ì´ ì•„ë‹˜! ì˜¤ì§ **Seizure ì˜ˆë°©(Neuroprotection)** ëª©ì .\n- **Mechanism:** Neuronal membrane stabilizing.\n- **Toxicity Signs (ìˆœì„œëŒ€ë¡œ ì§„í–‰):**\n    1. Loss of Deep Tendon Reflexes (DTRs) - **First sign!** â˜…\n    2. Respiratory Depression\n    3. Cardiac Arrest\n- **Antidote:** **Calcium Gluconate** (Keep it taped to the wall!).\n- **Contraindication:** Myasthenia Gravis, Renal failure (Magnesiumì€ ì‹ ì¥ìœ¼ë¡œ ë°°ì„¤ë¨ â†’ ì‹ ë¶€ì „ ì‹œ ë…ì„± ìœ„í—˜ ê¸‰ì¦).\n### **Fluid Management**\nPreeclampsia í™˜ìëŠ” í˜ˆê´€ íˆ¬ê³¼ì„±ì´ ë†’ì•„ì ¸ ìˆìŠµë‹ˆë‹¤(Leaky vessels). **Intravascularly dry**í•˜ì§€ë§Œ **Extravascularly wet** (Edema) ìƒíƒœì…ë‹ˆë‹¤. Diuretics(Furosemide)ëŠ” íë¶€ì¢…(Pulmonary edema)ì´ ì˜¨ ê²½ìš°ì—ë§Œ ì œí•œì ìœ¼ë¡œ ì‚¬ìš©í•©ë‹ˆë‹¤.\n---\n## 4. Specific Clinical Entities ğŸ”¥\n### **HELLP Syndrome**\nPreeclampsiaì˜ ì‹¬ê°í•œ ë³€í˜•\nâ†’ ddx. cholestasis, gallstone, hepatitis, HELLP\n- **H**emolysis (Schistocytes, Bilirubin â†‘) (microangiopathic hemolytic anemia)\n- **E**levated **L**iver enzymes\n- **L**ow **P**latelets\n- ì¹˜ë£Œ: **Immediate Delivery** (ì•ˆì •ì„ ì·¨í•œë‹¤ê³  ë‚˜ì•„ì§€ì§€ ì•ŠìŒ).\n### **Differential: Acute Fatty Liver of Pregnancy (AFLP) vs HELLP**\nHELLPì™€ ë¹„ìŠ·í•´ ë³´ì´ì§€ë§Œ ë‹¤ë¦…ë‹ˆë‹¤. ê°„ë¶€ì „(Liver failure) ì§•í›„ë¥¼ ì°¾ìœ¼ì„¸ìš”.\n- HELLPì™€ì˜ ê°ë³„ â˜…\n- hypertension ì—†ìŒ. platelet ì •ìƒì¸ë° PT/INR ìƒìŠ¹\n- **Key Features:** LIVER FAILURE\n    - â˜… Hypoglycemia (ì €í˜ˆë‹¹)\n    - â˜… Coagulopathy (PT/INR ì—°ì¥) / DIC\n        - HELLPëŠ” DICê°€ ë‚˜íƒ€ë‚˜ë„ ë‚˜ì¤‘ì— ë‚˜íƒ€ë‚¨.\n        - AFLPëŠ” ì‘ê³ ì¸ìê°€ ì‚¬ë¼ì ¸ì„œ DICê°€ ê¸ˆë°© ë‚˜íƒ€ë‚¨. IV bleeding.\n    - Ammonia ìƒìŠ¹.\n- **Comparison:** HELLPëŠ” í˜ˆì†ŒíŒ ê°ì†Œì™€ ìš©í˜ˆì´ ë©”ì¸ì´ì§€ë§Œ, AFLPëŠ” \"ê°„ì´ ì¼ì„ ì•ˆ í•˜ëŠ”(Synthetic function failure)\" ìƒíƒœì…ë‹ˆë‹¤. ì €í˜ˆë‹¹ì´ ìˆìœ¼ë©´ AFLPë¥¼ ê°•ë ¥ ì˜ì‹¬!\n---","subject":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","page_title":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","episode":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","section_path":["LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12"],"source_doc_id":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","source_page":null,"source_anchor":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12-230","focus_area":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"recap_summary","text":"## 5. Rapid Fire Recap: Clinical Scenarios (Section 9.5) ğŸš€\nì˜¤ë””ì˜¤ ë§ˆì§€ë§‰ì— ë‚˜ì˜¨ 5ê°€ì§€ ì‹œë‚˜ë¦¬ì˜¤ ì •ë¦¬ì…ë‹ˆë‹¤. ì‹œí—˜ì¥ì—ì„œ ë°”ë¡œ ë– ì˜¬ë¦¬ì„¸ìš”!\n**Scenario 1: Early Onset HTN**\n- **Situation:** 12ì£¼ ì„ì‚°ë¶€, BP 150/90. ì†Œë³€ ê¹¨ë—í•¨.\n- **Diagnosis:** **Chronic Hypertension** (20ì£¼ ì´ì „).\n- **Action:** Monitor, treat if severe.\n**Scenario 2: The Crash Section**\n- **Situation:** 38ì£¼, BP 160/110, ë‘í†µ(Headache), ë‹¨ë°±ë‡¨ 3+.\n- **Diagnosis:** **Preeclampsia with Severe Features**.\n- **Action:** **Stabilize & Deliver**. (IV Magnesium Sulfate + IV Antihypertensives + Delivery).\n**Scenario 3: The Toxic Patient**\n- **Situation:** Mag drops ë‹¬ê³  ìˆëŠ” í™˜ì. DTR ì†Œì‹¤(Reflexes absent), í˜¸í¡ìˆ˜ ê°ì†Œ.\n- **Diagnosis:** **Magnesium Toxicity**.\n- **Action:** Stop Mag â†’ Give **Calcium Gluconate**.\n**Scenario 4: The Mimic**\n- **Situation:** 36ì£¼, RUQ pain, BP ë†’ìŒ, Platelet 60k, Glucose 95 (ì •ìƒ).\n- **Diagnosis:** **HELLP Syndrome**.\n- **Action:** Delivery.","subject":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","page_title":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","episode":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","section_path":["LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12"],"source_doc_id":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","source_page":null,"source_anchor":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12-245","focus_area":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","tags":["usmle-step2","core","recap","diagnosis"]}
{"chunk_type":"transcript_chunk","text":"**Scenario 5: The Liver Failure**\n- **Situation:** 36ì£¼, Nausea/Vomiting, Jaundice, Glucose 40 (Hypoglycemia!), High INR.\n- **Diagnosis:** **Acute Fatty Liver of Pregnancy (AFLP)**.\n- **Action:** Emergency Delivery + Glucose support.\n---\n**Next Step for You:**\nChronic HTN í™˜ìì—ì„œ superimposed preeclampsiaë¥¼ ê°ë³„í•˜ëŠ” ê²ƒì´ ê½¤ ê¹Œë‹¤ë¡œìš¸ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ì™€ ê´€ë ¨ëœ **\"Superimposed Preeclampsia ì§„ë‹¨ ê¸°ì¤€ê³¼ Baseline w/u\"**ì— ëŒ€í•´ ë” ìì„¸íˆ ì •ë¦¬í•´ ë“œë¦´ê¹Œìš”?","subject":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","page_title":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","episode":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","section_path":["LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12"],"source_doc_id":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","source_page":null,"source_anchor":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12-255","focus_area":"LM_obs1 2f646f2986ee80d3a4e8c9b5ab8a0b12","tags":["usmle-step2","core","diagnosis"]}
{"chunk_type":"transcript_chunk","text":"# LM_obs2\n\"Hello and welcome back to the Wards. I'm your attending for this rotation. And I'm your senior resident, here to make sure we stay strictly evidence-based and, you know, maybe keep the attending from wandering off into too many back-in-my-day stories. Fair enough. Today we are doing a dedicated deep dive for the student out there. That's you getting ready to crush the USMLE Step 2 CK. Yep. We have a specific mission today. We really want to bridge that gap between the uh, the dry physiology you read in textbooks...\"\n---\n# Section 10: Gestational Diabetes (GDM)\n## 1. Introduction & Pathophysiology ğŸ§ \nì„ì‹ ì„± ë‹¹ë‡¨(GDM)ëŠ” ë‹¨ìˆœí•œ ê³ í˜ˆë‹¹ì´ ì•„ë‹ˆë¼ íƒœë°˜ê³¼ í˜¸ë¥´ëª¬ì˜ **Physiological Takeover**ì…ë‹ˆë‹¤.\n- **Case Scenario:** 30ì„¸ ì‚°ëª¨ (G2P1), ì„ì‹  26ì£¼. ì¦ìƒ ì—†ìŒ(Asymptomatic). í•˜ì§€ë§Œ Pre-pregnancy BMI 32.\n- **The \"Why\" (Pathophysiology):**\n    - í•µì‹¬ ë²”ì¸: **Placenta**ì—ì„œ ë¶„ë¹„ë˜ëŠ” **Human Placental Lactogen (HPL)** (a.k.a hCS).\n    - **ê¸°ì „:** HPLì€ ì‚°ëª¨ì—ê²Œ **Insulin Resistance**ë¥¼ ìœ ë°œí•©ë‹ˆë‹¤.\n    - **ëª©ì :** ì‚°ëª¨ì˜ ì„¸í¬ê°€ í¬ë„ë‹¹ì„ ì„­ì·¨í•˜ëŠ” ê²ƒì„ ë§‰ì•„ íƒœì•„ì—ê²Œ ë” ë§ì€ Glucoseë¥¼ ë³´ë‚´ê¸° ìœ„í•¨ (Fetus acts like a parasite ğŸ¦ ).\n    - **Timing:** íƒœë°˜ì´ ì»¤ì§ˆìˆ˜ë¡ HPL ë¶„ë¹„ëŸ‰ ì¦ê°€ â†’ ì„ì‹  í›„ê¸°(Late 2nd/Early 3rd trimester)ì— Insulin resistanceê°€ í”¼í¬ë¥¼ ì°ìŒ.\n    - ì‚°ëª¨ì˜ ì·Œì¥ì´ ì´ ì €í•­ì„±ì„ ì´ê²¨ë‚¼ ë§Œí¼ ì¶©ë¶„í•œ Insulinì„ ëª» ë§Œë“¤ì–´ë‚´ë©´ **GDM** ë°œìƒ.\n## 2. Screening Timeline & Risk Factors ğŸ—“ï¸\nGDM ìŠ¤í¬ë¦¬ë‹ì€ íƒ€ì´ë°ì´ ìƒëª…ì…ë‹ˆë‹¤. HPL ë ˆë²¨ì´ í”¼í¬ì¸ ì‹œì ì— ë§ì¶°ì•¼ í•©ë‹ˆë‹¤.\n- **Standard Screening:** **24-28 Weeks** (ì´ë•Œê°€ HPL í”¼í¬).\n- **ğŸš¨ High Risk Group (The Trap):**\n    - ê³ ìœ„í—˜êµ°ì€ 24ì£¼ê¹Œì§€ ê¸°ë‹¤ë¦¬ë©´ ì•ˆ ë©ë‹ˆë‹¤. **ì²« ë°©ë¬¸(First prenatal visit) ì‹œ ì¦‰ì‹œ ìŠ¤í¬ë¦¬ë‹**í•´ì•¼ í•©ë‹ˆë‹¤.\n    - ë§Œì•½ ì²« ë°©ë¬¸ ìŠ¤í¬ë¦¬ë‹ì´ Negativeë¼ë©´? â†’ 24-28ì£¼ì— ë‹¤ì‹œ **Rescreening** (HPL surge ë•Œë¬¸).\n### â˜… High Risk Flags (BMI > 30 + 1 Risk Factor)\në¹„ë§Œ(Obesity)ì´ ë² ì´ìŠ¤ë¼ì¸ì´ë©°, ë‹¤ìŒ ì¤‘ í•˜ë‚˜ë¼ë„ ìˆìœ¼ë©´ ì¦‰ì‹œ ê²€ì‚¬:\n1. Prior Gestational Diabetes (ì´ì „ ì„ì‹  ë•Œ GDM ë³‘ë ¥)\n2. Macrosomic infant history (>4000g or 4500g)\n3. Family History of DM (1st degree relative)\n4. PCOS (Polycystic Ovary Syndrome)\n5. Maternal Age > 40\n## 3. The Two-Step Testing Protocol ğŸ§ª\nUSMLE BoardsëŠ” ì´ ì•Œê³ ë¦¬ì¦˜ì„ ì‚¬ë‘í•©ë‹ˆë‹¤. í™˜ìë“¤ì´ ì‹«ì–´í•˜ëŠ” ë§›ì—†ëŠ” \"Glucola\"ë¥¼ ë§ˆì…”ì•¼ í•©ë‹ˆë‹¤.\n| **Step** | **Test Name** | **Protocol** | **Cutoff / Criteria** |\n| --- | --- | --- | --- |\n| **Step 1** | **50g Glucose Challenge Test (GCT)** | **Non-fasting** (ê¸ˆì‹ ë¶ˆí•„ìš”).\n1ì‹œê°„ í›„ í˜ˆë‹¹ ì¸¡ì •. | **> 140 mg/dL**\nì´ ë„˜ìœ¼ë©´ Step 2ë¡œ ì§„í–‰ (Screen Positive). |\n| **Step 2** | **100g Glucose Tolerance Test (GTT)** | **Fasting** (ê¸ˆì‹ í•„ìˆ˜).\nê³µë³µ, 1hr, 2hr, 3hr í˜ˆë‹¹ ì¸¡ì • (ì´ 4ë²ˆ). | **Carpenter-Coustan Criteria** (ì•„ë˜ ì°¸ì¡°).\nâ˜… **2ê°œ ì´ìƒì˜ ìˆ˜ì¹˜**ê°€ ë¹„ì •ìƒì¼ ë•Œ GDM í™•ì§„. |\n### â˜… Step 2 Cutoffs (Memorize These!) ğŸ”¢\nìš´ì „ ì¤‘ì´ë¼ë©´ ì°¨ë¥¼ ì„¸ìš°ê³  ì™¸ìš°ì„¸ìš”! (High Yield)\n- **Fasting:** 95\n- **1 Hour:** 180\n- **2 Hour:** 155\n- **3 Hour:** 140\n    - *(Tip: 180 -> 155 -> 140 ìˆœìœ¼ë¡œ ë–¨ì–´ì§)*\n    - ì°¸ê³ : ìˆ˜ì¹˜ í•˜ë‚˜ë§Œ íŠ€ëŠ” ê²½ìš°(One abnormal value)ëŠ” ì¼ë¶€ ì˜ì‚¬ë“¤ì´ 'Glucose Intolerance'ë¡œ ë³´ê¸°ë„ í•˜ì§€ë§Œ, **Board ì‹œí—˜ ê¸°ì¤€ìœ¼ë¡œëŠ” 2ê°œ ì´ìƒ íŠ€ì–´ì•¼ GDM ì§„ë‹¨**ì…ë‹ˆë‹¤.","subject":"LM_obs2 2f646f2986ee80f98092f841aa85480b","page_title":"LM_obs2 2f646f2986ee80f98092f841aa85480b","episode":"LM_obs2 2f646f2986ee80f98092f841aa85480b","section_path":["LM_obs2 2f646f2986ee80f98092f841aa85480b"],"source_doc_id":"LM_obs2 2f646f2986ee80f98092f841aa85480b","source_page":null,"source_anchor":"LM_obs2 2f646f2986ee80f98092f841aa85480b-1","focus_area":"LM_obs2 2f646f2986ee80f98092f841aa85480b","tags":["usmle-step2","core","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"## 4. Management Hierarchy ğŸ’Š\nì¹˜ë£Œì˜ ëª©í‘œëŠ” ì—„ê²©í•œ í˜ˆë‹¹ ì¡°ì ˆì…ë‹ˆë‹¤.\n### 1st Line: Diet & Exercise (Lifestyle) ğŸ¥¦\n- **Diet is King.** íƒ„ìˆ˜í™”ë¬¼ ì œí•œ(Carb restriction), ì‹í›„ ê±·ê¸° ë“±.\n- ëŒ€ë¶€ë¶„ì˜ í™˜ìëŠ” ì‹ì´ìš”ë²•ë§Œìœ¼ë¡œ ì¡°ì ˆ ê°€ëŠ¥í•©ë‹ˆë‹¤.\n- **Glycemic Targets (Goals):**\n    - Fasting: â‰¤ 95\n    - 1-hr Postprandial: â‰¤ 140\n    - 2-hr Postprandial: â‰¤ 120\n### 2nd Line: Pharmacotherapy ğŸ’‰\n- ì‹ì´ìš”ë²• ì‹¤íŒ¨ ì‹œ (Fasting > 95 ì§€ì†ë˜ê±°ë‚˜ Postprandial ìˆ˜ì¹˜ ì¡°ì ˆ ì‹¤íŒ¨).\n- **Gold Standard:** **Insulin**\n    - **ì´ìœ :** ì¸ìŠë¦°ì€ **íƒœë°˜ì„ í†µê³¼í•˜ì§€ ì•ŠìŒ(Does NOT cross the placenta)**. íƒœì•„ì—ê²Œ ì§ì ‘ì ì¸ ì˜í–¥ì„ ì£¼ì§€ ì•Šìœ¼ë¯€ë¡œ ê°€ì¥ ì•ˆì „.\n- *Note on Oral meds:* Metforminì´ë‚˜ Glyburideë„ ì‹¤ì œ ì„ìƒì—ì„œ ì“°ì´ì§€ë§Œ, ì´ ì•½ë“¤ì€ íƒœë°˜ì„ í†µê³¼í•©ë‹ˆë‹¤. **Board Exam ì •ë‹µì€ í•­ìƒ Insulinì…ë‹ˆë‹¤.**\n## 5. Fetal & Neonatal Complications ğŸ‘¶\n\"So What?\" ì™œ ìš°ë¦¬ê°€ í˜ˆë‹¹ì— ì§‘ì°©í•˜ëŠ”ê°€? ì‹œê¸°ì— ë”°ë¼ í•©ë³‘ì¦ì´ ë‹¤ë¦…ë‹ˆë‹¤.\n### A. Early Pregnancy (1st Trimester) - Pre-existing DM Risks âš ï¸\n- ì´ê±´ GDM(24ì£¼ ì´í›„ ë°œìƒ)ë³´ë‹¤ëŠ” **Pre-existing DM (Type 1 or 2)** í™˜ìì—ê²Œ í•´ë‹¹.\n- ê³ í˜ˆë‹¹ì´ **Teratogen**ìœ¼ë¡œ ì‘ìš©í•˜ì—¬ Organogenesis ë°©í•´.\n- **Risks:**\n    - Congenital Heart Defects (Transposition of Great Vessels ë“±).\n    - Neural Tube Defects.\n    - **Caudal Regression Syndrome (Sacral Agenesis):** í•˜ë°˜ì‹ ì´ ì œëŒ€ë¡œ ë°œë‹¬í•˜ì§€ ì•ŠëŠ” í¬ê·€ë³‘. **Classic High Yield Association.**\n### B. Late Pregnancy (GDM Risks) - Macrosomia ğŸ˜\n- **Mechanism:** Maternal Hyperglycemia â†’ Fetal Hyperglycemia â†’ Fetal Pancreasê°€ ë°˜ì‘í•˜ì—¬ **Fetal Hyperinsulinemia** ìœ ë°œ.\n    - Insulinì€ ê°•ë ¥í•œ **Growth Hormone**ì„.\n- **Result:** **Macrosomia** (ê±°ëŒ€ì•„).\n    - **Asymmetric Growth:** ë¨¸ë¦¬ë³´ë‹¤ **ì–´ê¹¨ì™€ ëª¸í†µ(Trunk)**ì— ì§€ë°©/ê¸€ë¦¬ì½”ê²ì´ ì¶•ì ë¨.\n    - **Complication:** **Shoulder Dystocia** (ì–´ê¹¨ ë‚œì‚°). ë¨¸ë¦¬ëŠ” ë‚˜ì™”ëŠ”ë° ì–´ê¹¨ê°€ ì¹˜ê³¨(Pubic bone)ì— ê±¸ë¦¼.\n    - **Injury Risk:** Clavicle Fracture, Brachial Plexus Injury (**Erb's Palsy** - C5/C6 damage, Waiter's tip hand).\n### C. Neonatal Complications (After Birth) ğŸ“‰\níƒ¯ì¤„ì„ ìë¥´ëŠ” ìˆœê°„(Cord clamping), ì—„ë§ˆë¡œë¶€í„° ì˜¤ë˜ Sugar supplyëŠ” ëŠê¸°ì§€ë§Œ ì•„ê¸° ëª¸ì†ì˜ **Insulinì€ ì—¬ì „íˆ ë†’ìŒ**.\n1. **Neonatal Hypoglycemia:** ê°€ì¥ í”í•¨. íƒœì–´ë‚˜ìë§ˆì í˜ˆë‹¹ ëš ë–¨ì–´ì§ â†’ ì¦‰ì‹œ ìˆ˜ìœ (Feed) í•„ìš”.\n2. **Polycythemia:** íƒœì•„ì˜ ëŒ€ì‚¬ëŸ‰ ì¦ê°€ â†’ ì‚°ì†Œ ìš”êµ¬ëŸ‰ ì¦ê°€(Hypoxia) â†’ EPO ì¦ê°€ â†’ RBC ê³¼ë‹¤ ìƒì„±. (í”¼ê°€ ëˆì í•´ì§/Sludge).\n3. **Hyperbilirubinemia (Jaundice):** ê³¼ë‹¤í•œ RBCê°€ ê¹¨ì§€ë©´ì„œ í™©ë‹¬ ë°œìƒ.\n4. **Hypocalcemia & Hypomagnesemia:** ì‚°ëª¨ì˜ Osmotic diuresisë¡œ ì¸í•´ ë§ˆê·¸ë„¤ìŠ˜ì´ ë¹ ì ¸ë‚˜ê°€ê³ (ë‹¹ë‡¨ë¡œ ë§ˆê·¸ë„¤ìŠ˜ ë¶€ì¡±..!), ì—„ë§ˆë„ ë§ˆê·¸ë„¤ìŠ˜ ì—†ê³  ì• ê¸°ë„ ë§ˆê·¸ë„¤ìŠ˜ ì—†ê³ . ì´ëŠ” íƒœì•„ì˜ PTH ë¶„ë¹„ë¥¼ ì–µì œ(Suppression)í•˜ì—¬ ì €ì¹¼ìŠ˜í˜ˆì¦ ìœ ë°œ (Jittery baby, Seizures).\n5. **RDS (Respiratory Distress Syndrome):** **Insulinì´ Cortisolì˜ ì‘ìš©ì„ ë°©í•´**í•˜ì—¬ Surfactant(ê³„ë©´í™œì„±ì œ) ìƒì„±ì„ ëŠ¦ì¶¤. (ë§Œì‚­ì•„ì¸ë°ë„ í ì„±ìˆ™ì´ ëŠ¦ì„ ìˆ˜ ìˆìŒ).\n6. Hypertrophic cardiomyopathy: ì‹¬ì¥ì— ê¸€ë¦¬ì½”ê²ì´ ìŒ“ì´ë©´ì„œ LVê°€ ì‘ì•„ì§„ë‹¤ â†’ transient â†’ ì•Œì•„ì„œ ì¢‹ì•„ì§.\n7. **Small Left Colon Syndrome:** (Trivia point) Transient obstruction related to DM.\n## 6. Postpartum Follow-up ğŸ¥\nì•„ê¸°ë¥¼ ë‚³ì•˜ë‹¤ê³  ëì´ ì•„ë‹™ë‹ˆë‹¤. ì‚°ëª¨ëŠ” ë¯¸ë˜ì˜ Type 2 DM ê³ ìœ„í—˜êµ°ì…ë‹ˆë‹¤.\nì¶œì‚° í›„ hplì´ ì¤„ë©´ì„œ ë‹¹ë‡¨ê°€ ì¢‹ì•„ì ¸ì•¼í•˜ëŠ”ë° ì•ˆì¢‹ì•„ì§€ë©´..? ì›ë˜ T2DMì´ ìˆë˜ê±°ì•„ëƒ?í•˜ê³  ê²€ì‚¬!\n1. **Immediate:** ì¶œì‚° í›„ 24-72ì‹œê°„ ë‚´ Fasting glucose ì²´í¬ (ê³ í˜ˆë‹¹ ì§€ì† ì—¬ë¶€ í™•ì¸).\n2. **Definitive Screening:** **6-12 Weeks Postpartum**.\n    - **75g 2-hour GTT** ì‹œí–‰.\n    - ì´ë•ŒëŠ” ì„ì‹  ê¸°ì¤€ì´ ì•„ë‹ˆë¼ **ì¼ë°˜ ì„±ì¸ ë‹¹ë‡¨ ê¸°ì¤€**ì„ ì ìš© (Fasting > 126, 2hr > 200, HbA1c > 6.5 ë“±).\n    - í‰ìƒ ë™ì•ˆ 1-3ë…„ ê°„ê²©ìœ¼ë¡œ ë‹¹ë‡¨ ìŠ¤í¬ë¦¬ë‹ ê¶Œê³ .\n---","subject":"LM_obs2 2f646f2986ee80f98092f841aa85480b","page_title":"LM_obs2 2f646f2986ee80f98092f841aa85480b","episode":"LM_obs2 2f646f2986ee80f98092f841aa85480b","section_path":["LM_obs2 2f646f2986ee80f98092f841aa85480b"],"source_doc_id":"LM_obs2 2f646f2986ee80f98092f841aa85480b","source_page":null,"source_anchor":"LM_obs2 2f646f2986ee80f98092f841aa85480b-21","focus_area":"LM_obs2 2f646f2986ee80f98092f841aa85480b","tags":["usmle-step2","core","treatment","pathophysiology"]}
{"chunk_type":"recap_summary","text":"# Rapid Fire Recap ğŸ”¥\n| **Clinical Scenario** | **Diagnosis / Key Fact** | **Action / Management** |\n| --- | --- | --- |\n| **First Visit:** BMI 32 + History of GDM | **High Risk** | **Immediate** 50g GCT screening (Don't wait for 24w). |\n| **Screening:** 50g GCT Result = 135 | **Normal (<140)** | Pass. Routine care. |\n| **Screening:** 50g GCT Result = 150 | **Positive Screen** | Proceed to **Step 2**:  95 80 55 040 |\n| **Diagnosis:** Fasting 98, 1hr 190 (Two abnormal) | **Gestational Diabetes 95 80 55 40** | **1st Line:** Diet & Exercise + Glucose monitoring (4x/day). |\n| **Management:** Diet fails (Fasting consistently >95) | **Uncontrolled GDM** | **Start Insulin** (Gold Standard). Avoid oral meds on boards. |\n| **Fetus:** Sacral Agenesis (Caudal Regression) | **Pre-existing DM** | This is NOT from GDM; indicates uncontrolled DM in 1st trimester. (ì›ë˜ìˆë˜ê±°) |\n| **Neonate:** Born to GDM mom, \"Jittery\" or seizing | **Hypocalcemia / Hypoglycemia** | Check Glucose first, then Calcium/Magnesium. |\n| **Complication:** GDM mom, term infant with respiratory distress | **RDS (Insulin blocks surfactant)** | Unlike preeclampsia (stress matures lungs), DM delays lung maturity. |\n| **Postpartum:** GDM resolved after birth | **Future Risk** | **2hr 75g GTT at 6-12 weeks** postpartum. |\n**â˜… High Yield Takeaway:**\n- **Pathophysiology:** HPL causing insulin resistance.\n- **Diagnosis:** Two abnormal values on 3hr GTT.\n- **Treatment:** Diet first â†’ Insulin second.\n- **Fetal Risk:** Macrosomia (Shoulder Dystocia) for GDM vs. Congenital Anomalies for Pre-existing DM.\n---\n# Section 11: Pregnancy, Labor & Delivery\n<aside>\nğŸ’¡\nWombì´ ì•ˆì „í• ê¹Œ NICUê°€ ì•ˆì „í• ê¹Œì— ëŒ€í•œ ê³ ë¯¼.","subject":"LM_obs2 2f646f2986ee80f98092f841aa85480b","page_title":"LM_obs2 2f646f2986ee80f98092f841aa85480b","episode":"LM_obs2 2f646f2986ee80f98092f841aa85480b","section_path":["LM_obs2 2f646f2986ee80f98092f841aa85480b"],"source_doc_id":"LM_obs2 2f646f2986ee80f98092f841aa85480b","source_page":null,"source_anchor":"LM_obs2 2f646f2986ee80f98092f841aa85480b-41","focus_area":"LM_obs2 2f646f2986ee80f98092f841aa85480b","tags":["usmle-step2","core","recap","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"</aside>\n## 1. Introduction: The Goldilocks Problem ğŸ»\nLabor & DeliveryëŠ” ë³‘ì›ì—ì„œ ê°€ì¥ **High Stakes Environment** ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. ì´ë²ˆ ì„¸ì…˜ì˜ í•µì‹¬ í…Œë§ˆëŠ” **\"Goldilocks Problem\"**ì…ë‹ˆë‹¤.\n- **Too Early:** Baby tries to exit too early (Preterm Labor).\n- **Too Late:** Baby refuses to leave (Postterm Pregnancy).\n- **Goal:** Gestational Ageì™€ Management Algorithmì„ ì—°ê²°í•˜ì—¬ \"Why\"ë¥¼ ì´í•´í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.\n---\n## 2. Preterm Labor (11.1) â±ï¸\n### 2.1. Diagnosis: The Big Two\në‹¨ìˆœíˆ Monitor ìƒì˜ Contraction ë§Œìœ¼ë¡œëŠ” ì¶©ë¶„í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤.\n1. **Regular Contractions**\n2. **Cervical Change:** Cervixê°€ 2cm ì´ìƒ Dilated ë˜ê±°ë‚˜ ë³€í™”ê°€ ìˆì–´ì•¼ \"Labor\"ì…ë‹ˆë‹¤.\n### 2.2. Risk Factors\n- **Short Interpregnancy Interval:** ì´ì „ ì¶œì‚° í›„ 6~18ê°œì›” ë¯¸ë§Œ. Bodyê°€ \"Restock\"í•  ì‹œê°„ì´ ë¶€ì¡±í–ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.\n- **Maternal Anemia & Low BMI (<18.5):** Nutritional Reserveê°€ ë¶€ì¡±í•œ ìƒíƒœì…ë‹ˆë‹¤.\n### 2.3. Management Zones (Zone Defense) ğŸ›¡ï¸\nGestational Ageì— ë”°ë¼ ì¹˜ë£Œ ì „ëµì´ ì™„ì „íˆ ë‹¬ë¼ì§‘ë‹ˆë‹¤.\n| **Zone** | **Weeks** | **Management Strategy** | **Key Drugs & Rationale** |\n| --- | --- | --- | --- |\n| **Zone 1 (Danger Zone)** | **< 32 Weeks** | **Full Court Press** (Aggressive) | â€¢ **Magnesium Sulfate:** â˜… **Neuroprotection** (Cerebral Palsy ì˜ˆë°©).\nâ€¢ **Indomethacin:** Tocolytic of choice. (Prostaglandin blocker).\nâ€¢ **Betamethasone (Steroids):** Lung maturation (Surfactant).\nâ€¢ **Penicillin:** GBS prophylaxis (if unknown/positive). |\n| **Zone 2 (Middle Ground)** | **32 - 34 Weeks** | Switch Tocolytics | â€¢ **Stop Magnesium:** Neuroprotection ë°ì´í„°ê°€ 32ì£¼ ì´í›„ì—” ë¶ˆì¶©ë¶„í•¨.\nâ€¢ **Switch to Nifedipine (CCB):** â˜… **Indomethacin ì¤‘ë‹¨ í•„ìˆ˜**. Indomethacinì€ **Ductus Arteriosus**ë¥¼ ì¡°ê¸° íì‡„(Premature closure)ì‹œì¼œ Pulmonary HTN/Heart Failure ìœ ë°œ ê°€ëŠ¥.\nâ€¢ **Steroids & PCN:** ìœ ì§€. |\n| **Zone 3 (Late Preterm)** | **34 - 37 Weeks** | **Let it happen** | â€¢ **No Tocolysis:** ì–µì§€ë¡œ ë§‰ì§€ ì•ŠìŠµë‹ˆë‹¤.\nâ€¢ **No Magnesium**.\nâ€¢ Survival rateê°€ ì¢‹ìœ¼ë¯€ë¡œ ìì—°ìŠ¤ëŸ¬ìš´ ì§„í–‰ì„ í—ˆìš©í•©ë‹ˆë‹¤. |\n## 3. Labor Physiology & Decelerations (11.2) ğŸ“‰\nContractionê³¼ Fetal Heart Rateì˜ ê´€ê³„ë¥¼ í•´ì„í•˜ëŠ” ê²ƒì´ L&Dì˜ í•µì‹¬ì…ë‹ˆë‹¤.\n- **Early Decelerations:**\n    - Contractionì˜ Peakì™€ Heart rateì˜ Valleyê°€ ì •í™•íˆ ì¼ì¹˜(Symmetric/Mirror Image).\n    - **Cause:** **Fetal Head Compression** (Vagal nerve stimulation -> HR drop).\n    - **Meaning:** Physiological (Reflex). ë³´í†µ Labor ì§„í–‰ ì¤‘ì„ì„ ì˜ë¯¸í•˜ë©° ìœ„í—˜í•˜ì§€ ì•ŠìŒ.\n- **Variable Decelerations:**\n    - Contractionê³¼ ê´€ê³„ì—†ì´ ë¶ˆê·œì¹™í•˜ê²Œ ë°œìƒ, ëª¨ì–‘ì´ **Sharp \"V\" or \"W\" shape**. 30ì´ˆ ì´ë‚´ì— ë°”ë‹¥ì„ ì°ê³  ì˜¬ë¼ì˜´.\n    - **Cause:** **Cord Compression** (íƒ¯ì¤„ì´ ëˆŒë¦¼). ë¬¼í˜¸ìŠ¤ë¥¼ ë°Ÿìœ¼ë©´? ì•„ì£¼ ê¸ˆë°© ë°”ë¡œ í˜¸ìŠ¤ì—ì„œ ë¬¼ì´ ì•ˆë‚˜ì˜¨ë‹¤. ê·¸ë˜ì„œ ë¹¨ë¦¬ V shape. ê·¸ë¦¬ê³  ë¬¼ í˜¸ìŠ¤ì—ì„œ ë°œì„ ë–¼ë©´ ë°”ë¡œ ë¬¼ì´ ë‚˜ì˜¨ë‹¤.\n    - **Context:** ì£¼ë¡œ ì–‘ìˆ˜ê°€ í„°ì§„ í›„(**ROM**) í˜¹ì€ **Low Fluid (Oligohydramnios)** ìƒíƒœì—ì„œ ë°œìƒ","subject":"LM_obs2 2f646f2986ee80f98092f841aa85480b","page_title":"LM_obs2 2f646f2986ee80f98092f841aa85480b","episode":"LM_obs2 2f646f2986ee80f98092f841aa85480b","section_path":["LM_obs2 2f646f2986ee80f98092f841aa85480b"],"source_doc_id":"LM_obs2 2f646f2986ee80f98092f841aa85480b","source_page":null,"source_anchor":"LM_obs2 2f646f2986ee80f98092f841aa85480b-51","focus_area":"LM_obs2 2f646f2986ee80f98092f841aa85480b","tags":["usmle-step2","core","diagnosis","treatment","tree"]}
{"chunk_type":"transcript_chunk","text":"---\n## 4. Breech Presentation & Non-Viable Fetus (11.3) ğŸ¦¶\n**Clinical Vignette:** 28ì£¼, Prenatal care ì—†ìŒ, **No Fluid (Anhydramnios)**, ì´ˆìŒíŒŒìƒ **Anencephaly** (Brain/Skull ë¯¸ë°œë‹¬) í™•ì¸ë¨. ì•„ê¸°ëŠ” Breech ìƒíƒœ.\n- **Dilemma:** ë³´í†µ BreechëŠ” Head entrapment ìœ„í—˜ ë•Œë¬¸ì— C-sectionì„ í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ ê²½ìš°ëŠ”?\n- **Management:** **Vaginal Delivery**.\n- **Rationale:** Fetusê°€ **Non-viable** (ìƒì¡´ ë¶ˆê°€ëŠ¥)í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì‚°ëª¨ì—ê²Œ Major Surgery (C-section)ì˜ ìœ„í—˜ì„ ê°ìˆ˜í•˜ê²Œ í•˜ë©´ì„œ ìƒì¡´í•  ìˆ˜ ì—†ëŠ” ì•„ê¸°ë¥¼ êº¼ë‚¼ ì´ìœ ëŠ” ì—†ìŠµë‹ˆë‹¤.\n## 5. ECV (11.4) â\n- 37ì£¼ ë„˜ì–´ì„œ\n- ê¸ˆê¸°: ruptured membranes (ì–‘ìˆ˜í„°ì§), ì• ê¸° distress ë“±\n---\n## 6. Internal Podalic Version\n- twin A ë°‘ì—ëŠ” ë‚˜ì˜¤ê³  twin Bì— ëŒ€í•´ì„œ í•˜ëŠ” ì²˜ì¹˜ì„.\n- Aë‚˜ì˜¤ê³  Bê°€ ì € ìœ„ì—ì„œ ì•ˆë‚˜ì˜¬ë•Œ, ì†ë„£ì–´ì„œ B ì¡ê³  breechë¡œ ëŒì–´ë‹¹ê²¨ì„œ ë¶„ë§Œ\n---\n## 5. Shoulder Dystocia (11.6) ğŸ¢\n- **Sign:** **Turtle Sign** (ë¨¸ë¦¬ê°€ ë‚˜ì™”ë‹¤ê°€ ë‹¤ì‹œ ë“¤ì–´ê°€ëŠ” í˜„ìƒ). Anterior shoulderê°€ Pubic bone ë’¤ì— ê±¸ë¦° ìƒíƒœì…ë‹ˆë‹¤.\n- **Risk Factors:** **Macrosomia** (GDM, Post-dates).\n- **Action:** Obstetric Emergency. ì¦‰ì‹œ maneuvers ì‹œí–‰ (McRoberts ë“± - ì˜¤ë””ì˜¤ì—ëŠ” êµ¬ì²´ì  ìˆ ê¸° ì´ë¦„ ëŒ€ì‹  Emergencyë¼ëŠ” ì  ê°•ì¡°).\n---\n## 6. Postterm Pregnancy (11.7) ğŸ“…\n**Doorway Thought:** 42ì£¼ ì‚°ëª¨ê°€ ë‚´ì›. \"ì™œ ì•„ì§ ì§„í†µì´ ì—†ë‚˜ìš”?\"ë¼ê³  ë¬»ìŠµë‹ˆë‹¤.\n- **Definitions:**\n    - Late Term: 41 weeks ~ 41w6d.\n    - Postterm: **> 42 weeks**.\n- **Concept: The Placental Battery** ğŸ”‹\n    - íƒœë°˜ì€ ì˜êµ¬ì ì´ì§€ ì•ŠìŠµë‹ˆë‹¤. 40ì£¼ê°€ ë„˜ì–´ê°€ë©´ \"Battery\"ê°€ ë°©ì „ë˜ê¸° ì‹œì‘í•©ë‹ˆë‹¤(Calcification).\n    - Perfusionì´ ë–¨ì–´ì§€ë©´ íƒœì•„ëŠ” í˜ˆë¥˜ë¥¼ Brain/Heartë¡œ ì¬ë¶„ë°°(Redistribute)í•˜ê³  Kidneyë¡œ ê°€ëŠ” í˜ˆë¥˜ë¥¼ ì¤„ì…ë‹ˆë‹¤.\n    - Kidney í˜ˆë¥˜ ê°ì†Œ â†’ Fetal Urine ê°ì†Œ â†’ **Oligohydramnios** (ì–‘ìˆ˜ ê°ì†Œ) â†’ **Cord Compression** â†’ **Variable Decelerations**.\n- **Risks (Postterm):**\n    1. **Dysmaturity Syndrome:** ì²´ì¤‘ ê°ì†Œ(Starving), í”¼ë¶€ê°€ ë²—ê²¨ì§(Peeling skin), Wasted appearance.\n    2. **Macrosomia:** ì¼ë¶€ëŠ” ê³„ì† ì»¤ì ¸ì„œ ë‚œì‚° ìœ ë°œ.\n    3. **Stillbirth:** ê°€ì¥ ìµœì•…ì˜ ê²°ê³¼.\n- **Management:**\n    - **Do not wait indefinitely.** 41~42ì£¼ ì‚¬ì´ì— Inductionì„ ê¶Œì¥í•©ë‹ˆë‹¤.\n    - 43ì£¼ê¹Œì§€ ê°€ëŠ” ê²ƒì€ í˜„ëŒ€ ì˜í•™ì—ì„œ ê±°ì˜ í—ˆìš©ë˜ì§€ ì•ŠìŠµë‹ˆë‹¤.\n---","subject":"LM_obs2 2f646f2986ee80f98092f841aa85480b","page_title":"LM_obs2 2f646f2986ee80f98092f841aa85480b","episode":"LM_obs2 2f646f2986ee80f98092f841aa85480b","section_path":["LM_obs2 2f646f2986ee80f98092f841aa85480b"],"source_doc_id":"LM_obs2 2f646f2986ee80f98092f841aa85480b","source_page":null,"source_anchor":"LM_obs2 2f646f2986ee80f98092f841aa85480b-71","focus_area":"LM_obs2 2f646f2986ee80f98092f841aa85480b","tags":["usmle-step2","core","treatment"]}
{"chunk_type":"recap_summary","text":"## 7. Rapid Fire Recap ğŸ”¥\nì˜¤ë””ì˜¤ì˜ ë§ˆì§€ë§‰ Recap ì„¸ì…˜ì„ ë°”íƒ•ìœ¼ë¡œ ì •ë¦¬í•œ High-Yield Summaryì…ë‹ˆë‹¤.\n| **Scenario** | **Diagnosis/Context** | **Key Action / Fact** |\n| --- | --- | --- |\n| **29 Weeks Labor** | Preterm Labor (Zone 1) | **Indomethacin** (Tocolytic) + **Mg Sulfate** (Neuroprotection) |\n| **33 Weeks Labor** | Preterm Labor (Zone 2) | Switch from Indomethacin to **Nifedipine** (CCB). (Avoid Indomethacin d/t PDA closure risk) |\n| **Deep \"V\" on Monitor** | Variable Deceleration | Think **Cord Compression** & **Low Fluid** (Oligohydramnios) |\n| **Postterm Fetus Risks** | Placental Insufficiency | **Macrosomia**, **Dysmaturity Syndrome**, **Oligohydramnios** |\n| **\"Placental Battery\"** | Postterm Physiology | Placenta ages â†’ Perfusion drops â†’ Fetus spares kidneys â†’ **Low Amniotic Fluid** |\n---\n# Section 12: Third Trimester Bleeding (Obstetrics Block)\n## 1. Introduction: High Yield & High Stakes ğŸš¨\nì´ ì„¹ì…˜ì€ ë‹¨ìˆœíˆ ì±…ë§Œ ì½ì€ í•™ìƒê³¼ **internì´ ë  ì¤€ë¹„ê°€ ëœ í•™ìƒ**ì„ ê°€ë¥´ëŠ” ì¤‘ìš”í•œ íŒŒíŠ¸ì…ë‹ˆë‹¤. Third trimester bleedingì€ ë‹¨ìˆœí•œ ì§„ë‹¨ ì²´í¬ë°•ìŠ¤ê°€ ì•„ë‹ˆë¼, **Motherì™€ Fetus ë‘ í™˜ìê°€ ì—°ê´€ëœ Physiological Crisis**ì…ë‹ˆë‹¤.\n- **Focus:** Source material Section 12 through 12.4.\n- **Goal:** Anatomyì™€ Managementë¥¼ ì—°ê²°í•˜ì—¬ Clinical Intuitionì„ ê¸°ë¥´ëŠ” ê²ƒ. (ì»¤í”¼ ë§ˆì‹¤ ì‹œê°„ì´ ìˆëŠ”ì§€, ë‹¹ì¥ ORë¡œ ë‹¬ë ¤ê°€ì•¼ í•˜ëŠ”ì§€ íŒë‹¨í•˜ëŠ” ëŠ¥ë ¥!)\n- **Mission:** **Triage**. 20ì£¼ ì´í›„ì˜ ì¶œí˜ˆ(Blood on the floor)ì€ ê°ˆë¦¼ê¸¸(Fork in the road)ê³¼ ê°™ìŠµë‹ˆë‹¤.\n    - One path is stable.\n    - The other is catastrophic.","subject":"LM_obs2 2f646f2986ee80f98092f841aa85480b","page_title":"LM_obs2 2f646f2986ee80f98092f841aa85480b","episode":"LM_obs2 2f646f2986ee80f98092f841aa85480b","section_path":["LM_obs2 2f646f2986ee80f98092f841aa85480b"],"source_doc_id":"LM_obs2 2f646f2986ee80f98092f841aa85480b","source_page":null,"source_anchor":"LM_obs2 2f646f2986ee80f98092f841aa85480b-88","focus_area":"LM_obs2 2f646f2986ee80f98092f841aa85480b","tags":["usmle-step2","core","recap","diagnosis","treatment"]}
